entertainment -WSS

entertainment

author：hotspot 2025-09-11 06:21:14 - browse：5

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Think you might have Covid

leisure time

WSS

The surgeon had a dilemma only a Nazi medical text could resolve

Dewpoint Therapeutics lays off staff after losing partnerships

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

The tragedy of Johnson & Johnson’s Covid vaccine

Emergency medicine has repudiated 'excited delirium.' Now what?

Biotech venture capitalists face new demands from investors

entertainment

entertainment

leisure time

Apple is now the first public company to be valued at $3 trillion

My yearlong odyssey to get my son’s ADHD medication covered

Supreme Court strikes down use of affirmative action

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

In age of alternative facts, a scholarly course on calling out crap

Biden's order seeks to regulate AI risk without stifling innovation

As demand for Covid shots wanes, Moderna seeks its next success

Eli Lilly, Pfizer, and others want in on the online prescription market

The high cost of giving birth even with insurance

Medtronic CEO on promising devices for diabetes, hypertension

knowledge

Testing for cancer recurrence creates a new limbo for patients

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Meta's Zuckerberg and Chan on track to put $50 billion into science

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

focus

leisure time

leisure time

focus